June 7, 2026 ADA2026: Oral NLRP3 Inhibitor BGE-102 Preserves Retinal Vascular Integrity in a Preclinical Model of Diabetic Retinopathy June 7, 2026 ADA2026: BGE-102, a Novel NLRP3 Inhibitor, Demonstrated Robust Anti-Inflammatory Activity in a Phase 1 Study in Healthy Volunteers and Participants with Obesity May 8, 2026 BioAge R&D Day Presentation April 21, 2026 BioAge Corporate Presentation
June 7, 2026 ADA2026: Oral NLRP3 Inhibitor BGE-102 Preserves Retinal Vascular Integrity in a Preclinical Model of Diabetic Retinopathy
ADA2026: Oral NLRP3 Inhibitor BGE-102 Preserves Retinal Vascular Integrity in a Preclinical Model of Diabetic Retinopathy
June 7, 2026 ADA2026: BGE-102, a Novel NLRP3 Inhibitor, Demonstrated Robust Anti-Inflammatory Activity in a Phase 1 Study in Healthy Volunteers and Participants with Obesity
ADA2026: BGE-102, a Novel NLRP3 Inhibitor, Demonstrated Robust Anti-Inflammatory Activity in a Phase 1 Study in Healthy Volunteers and Participants with Obesity
